Pharmaceutical agents that act as agonists or antagonists for NRs, such as tamoxifen for ER (used in breast cancer treatment), glitazones and thiazolidinediones for PPARγ (utilized in type II diabetes management), or dexamethasone for GR (applied in the treatment of inflammatory diseases), represent prevalent and widely employed therapeutic modalities [126, 128]. This evidence concerns the gene NR3C1 and breast cancer.